DTIL Precision Biosciences Inc

Price (delayed)

$13.04

Market cap

$90.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.36

Enterprise value

-$38.86M

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome ...

Highlights
Precision Biosciences's gross profit has soared by 88% YoY and by 18% from the previous quarter
Precision Biosciences's revenue has soared by 88% YoY and by 18% from the previous quarter
The company's equity has surged by 97% QoQ but it fell by 7% YoY

Key stats

What are the main financial stats of DTIL
Market
Shares outstanding
6.93M
Market cap
$90.31M
Enterprise value
-$38.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.42
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.68
Earnings
Revenue
$57.53M
EBIT
-$25.39M
EBITDA
-$17.99M
Free cash flow
-$72.99M
Per share
EPS
-$7.36
Free cash flow per share
-$14.42
Book value per share
$5.38
Revenue per share
$11.37
TBVPS
$36.43
Balance sheet
Total assets
$184.74M
Total liabilities
$147.54M
Debt
$8.59M
Equity
$37.21M
Working capital
$127.49M
Liquidity
Debt to equity
0.23
Current ratio
4.82
Quick ratio
4.49
Net debt/EBITDA
7.18
Margins
EBITDA margin
-31.3%
Gross margin
100%
Net margin
-48.1%
Operating margin
-75.5%
Efficiency
Return on assets
-16%
Return on equity
-92.9%
Return on invested capital
-1,439.9%
Return on capital employed
-16.8%
Return on sales
-44.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DTIL stock price

How has the Precision Biosciences stock price performed over time
Intraday
1.56%
1 week
12.22%
1 month
33.88%
1 year
-44.05%
YTD
19.09%
QTD
-3.83%

Financial performance

How have Precision Biosciences's revenue and profit performed over time
Revenue
$57.53M
Gross profit
$57.53M
Operating income
-$43.43M
Net income
-$27.67M
Gross margin
100%
Net margin
-48.1%
Precision Biosciences's gross profit has soared by 88% YoY and by 18% from the previous quarter
Precision Biosciences's revenue has soared by 88% YoY and by 18% from the previous quarter
DTIL's net margin has soared by 86% YoY and by 62% QoQ
The company's net income has surged by 75% YoY and by 55% QoQ

Growth

What is Precision Biosciences's growth rate over time

Valuation

What is Precision Biosciences stock price valuation
P/E
N/A
P/B
2.42
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.68
DTIL's EPS has soared by 78% year-on-year and by 54% since the previous quarter
The company's equity has surged by 97% QoQ but it fell by 7% YoY
DTIL's P/B is 40% below its 5-year quarterly average of 4.0 but 20% above its last 4 quarters average of 2.0
The P/S is 89% lower than the 5-year quarterly average of 10.4 but 13% higher than the last 4 quarters average of 1.0
Precision Biosciences's revenue has soared by 88% YoY and by 18% from the previous quarter

Efficiency

How efficient is Precision Biosciences business performance
DTIL's ROS has soared by 87% year-on-year and by 64% since the previous quarter
Precision Biosciences's ROA has soared by 63% YoY and by 54% from the previous quarter
Precision Biosciences's return on equity has surged by 54% QoQ and by 38% YoY
The return on invested capital is up by 40% since the previous quarter

Dividends

What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DTIL.

Financial health

How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 25% more than its total liabilities
DTIL's current ratio has surged by 77% since the previous quarter and by 34% year-on-year
Precision Biosciences's quick ratio has surged by 73% QoQ and by 32% YoY
DTIL's debt is 77% lower than its equity
The company's equity has surged by 97% QoQ but it fell by 7% YoY
DTIL's debt has shrunk by 68% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.